```
16104262D
 1
                                           HOUSE BILL NO. 1292
 2
                                 House Amendments in [] — February 12, 2016
 3
    A BILL to amend and reenact § 54.1-3452 of the Code of Virginia, relating to Schedule IV drugs;
 4
        eluxadoline.
 5
                                 Patron Prior to Engrossment—Delegate Pillion
 6
 7
                            Referred to Committee on Health, Welfare and Institutions
 8
 9
        Be it enacted by the General Assembly of Virginia:
    1. That § 54.1-3452 of the Code of Virginia is amended and reenacted as follows:
10
        § 54.1-3452. Schedule IV.
11
12
        The controlled substances listed in this section are included in Schedule IV unless specifically
13
    excepted or listed in another schedule:
        1. Any material, compound, mixture, or preparation which contains any quantity of the following
14
15
    substances having a potential for abuse associated with a depressant effect on the central nervous
16
    system:
        Alfaxalone (5[alpha]-pregnan-3[alpha]-ol-11,20-dione), previously spelled "alphaxalone," including its
17
    salts, isomers, and salts of isomers;
18
19
        Alprazolam;
20
        Barbital;
21
        Bromazepam;
22
        Camazepam;
        Carisoprodol;
23
24
        Chloral betaine;
25
        Chloral hydrate;
        Chlordiazepoxide;
26
27
        Clobazam;
        Clonazepam;
28
29
        Clorazepate;
30
        Clotiazepam;
31
        Cloxazolam;
        Delorazepam;
32
33
        Diazepam;
34
        Dichloralphenazone;
35
        Estazolam:
36
        Ethchlorvynol;
37
        Ethinamate:
        Ethyl loflazepate;
38
39
        Fludiazepam;
        Flunitrazepam;
40
41
        Flurazepam:
        Fospropofol;
42
43
        Halazepam;
        Haloxazolam:
44
45
        Ketazolam;
46
        Loprazolam;
47
        Lorazepam;
        Lormetazepam;
48
49
        Mebutamate;
50
        Medazepam;
51
        Methohexital;
52
        Meprobamate:
        Methylphenobarbital;
53
54
        Midazolam;
55
        [ Nimetazapam Nimetazepam ];
        Nitrazepam;
56
        Nordiazepam;
57
```

58

Oxazepam;

HB1292E 2 of 2

```
59
        Oxazolam;
60
       Paraldehyde;
61
       Petrichloral;
62
       Phenobarbital;
63
       Pinazepam;
64
       Prazepam;
65
        Quazepam;
       Suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1 -yl][5-methyl-2-
66
    (2H-1,2,3-triazol-2-yl) phenyl]methanone), including its salts, isomers, and salts of isomers;
67
68
        Temazepam;
69
       Tetrazepam;
        Triazolam:
70
71
       Zaleplon;
72
       Zolpidem;
73
       Zopiclone.
```

2. Any compound, mixture or preparation which contains any quantity of the following substances including any salts or isomers thereof:

Fenfluramine:

Lorcaserin.

76

77

78

80

81

82

83

84

85

93

94

95

96 97

98

99

100

101

102

103 104

105

106 107

108

109

110

111

112

3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Cathine (+)-norpseudoephedrine;

Diethylpropion;

Fencamfamin;

86 Fenproprex;

87 Mazindol;

88 Mefenorex;

89 Modafinil:

90 Phentermine;

Pemoline (including organometallic complexes and chelates thereof);

92 Pipradrol;

Sibutramine;

SPA (-)-1-dimethylamino-1, 2-diphenylethane.

4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxy butane);

Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;

- 2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol, its salts, optical and geometric isomers, and salts of such isomers, including tramadol.
- 5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including their salts:

Butorphanol (including its optical isomers);

Eluxadoline (including its optical isomers [and its salts, isomers, and salts of isomers]); Pentazocine.

- 6. The Board may except by regulation any compound, mixture, or preparation containing any depressant substance listed in subdivision 1 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.
- which have a depressant effect on the central nervous system.

 114 2. That the provisions of this act may result in a net increase in periods of imprisonment or commitment. Pursuant to § 30-19.1:4, the estimated amount of the necessary appropriation cannot be determined for periods of imprisonment in state adult correctional facilities; therefore, Chapter 665 of the Acts of Assembly of 2015 requires the Virginia Criminal Sentencing Commission to assign a minimum fiscal impact of \$50,000. Pursuant to § 30-19.1:4, the estimated amount of the necessary appropriation cannot be determined for periods of commitment to the custody of the

120 Department of Juvenile Justice.